MedTrace Logo

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 805

Last updated 2020-04-22

No results posted yet for this study

Summary

The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.

This study will also evaluate effectiveness of OAB therapies in routine clinical practice; identify factors associated with effectiveness and persistence of pharmacologic therapies in OAB participants; evaluate the Quality of Life (QoL) and treatment satisfaction of OAB therapies; as well as evaluate health care resource utilization (HCRU) and understand adverse events (AEs), serious adverse events (SAEs) and adverse drug reactions (ADRs) associated with OAB therapies.

Conditions

  • Overactive Bladder (OAB)

Interventions

DRUG

mirabegron

oral

DEVICE

solifenacin

oral

DRUG

darifenacin

oral

DRUG

imidafenacin

oral

DRUG

tolterodine

oral

DRUG

oxybutynin

oral

DRUG

trospium

oral

DRUG

fesoterodine

oral

DEVICE

propiverine

oral

Sponsors & Collaborators

  • Astellas Pharma Singapore Pte. Ltd.

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Singapore Pte. Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-19
Primary Completion
2020-03-30
Completion
2020-03-30

Countries

  • South Korea
  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03572231 on ClinicalTrials.gov